With the new funding, the company anticipates progressing its ‘lead’ preclinical assets towards clinical development. Credit: CrizzyStudio / Shutterstock.

Coave Therapeutics has raised €32m ($33m) in a Series A financing round for advancing its Advanced Vectors-Ligand Conjugates (ALIGATER) platform.

This platform claims to address the limitations in genetic payloads delivery to extra-hepatic tissues, including limited delivery efficiency, safety, and specificity of the tissue.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Novo Holdings and Bpifrance co-led the funding round, with additional participation from Invus and UI Investissement.

Current investors Fund+, Kurma Partners, Seroba Life Sciences, Turenne Capital, and Omnes Capital also contributed to the financing.

The ALIGATER platform allows for the ‘conjugation’ of targeting ligands on adeno-associated viruses (AAV) or non-viral vectors, improving delivery efficiency and tissue specificity. This approach also simplifies the manufacturing process by eliminating the need for prior AAV capsid modifications.

As a result, the company is poised to create gene therapies for a range of diseases, with a particular emphasis on the central nervous system (CNS), eye, and neuromuscular conditions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With the new funding, the company anticipates progressing its ‘lead’ preclinical assets towards clinical development and aims to move two development candidates to clinical trial application (CTA) or investigational new drug (IND)-enabling studies by next year.

In line with the financing, Emmanuelle Coutanceau from Novo Holdings and Jean Francois Morin from Bpifrance will join Coave’s board of directors.

Coave Therapeutics CEO Rodolphe Clerval said: “We are delighted to welcome this group of top-tier investors who share our vision for the ALIGATER platform. This funding is a critical milestone for Coave as we work to develop a new generation of targeted, safer, and more efficacious gene therapies.

“It also reinforces our ability to expand collaborations with pharma and biotech partners, driving innovation in the field of genetic medicines for a broad range of diseases.”

Headquartered in France, Coave is supported by a consortium of international life sciences investors.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.